Metrics to compare | ONCO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipONCOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.5x | −0.4x | −0.4x | |
PEG Ratio | 0.72 | 0.05 | 0.00 | |
Price/Book | 96.3x | 1.2x | 2.6x | |
Price / LTM Sales | 340.4x | 1.0x | 3.1x | |
Upside (Analyst Target) | - | 204.6% | 49.0% | |
Fair Value Upside | Unlock | 4.0% | 7.1% | Unlock |
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments in Canada. The company’s lead product candidate is ONC010, an inhibitor of the DNA repair enzyme polynucleotide kinase 3'-phosphatase (PNKP) in a nanoparticle formulation based on drug delivery technology. It also develops SynoGraph technology, an artificial intelligence-powered tool to accelerate precision oncology breakthroughs and de-risk drug development. In addition, the company engages in research and development activities. It has collaborations with Dalton Pharma Services, the University of Alberta and Cross Cancer Institute, Nucro-Technics Inc., and Avance Clinical Pty Ltd. Onco-Innovations Limited is headquartered in Calgary, Canada.